These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23861604)

  • 21. Denosumab - a new medication in the treatment of postmenopausal osteoporosis.
    Słopień R; Rynio P; Kubala E; Milewska E; Meczekalski B
    Prz Menopauzalny; 2017 Sep; 16(3):75-78. PubMed ID: 29507572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Denosumab: the era of targeted therapies in bone metastatic diseases.
    Santini D; Fratto ME; Vincenzi B; Napoli N; Galluzzo S; Tantardini M; Abbruzzese A; Caraglia M; Tonini G
    Curr Cancer Drug Targets; 2009 Nov; 9(7):834-42. PubMed ID: 20025571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Denosumab in patients with cancer-a surgical strike against the osteoclast.
    Brown JE; Coleman RE
    Nat Rev Clin Oncol; 2012 Jan; 9(2):110-8. PubMed ID: 22231759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
    Brufsky AM
    Oncologist; 2008 Feb; 13(2):187-95. PubMed ID: 18305064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
    Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S
    J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of bone metastases in refractory prostate cancer--role of denosumab.
    Paller CJ; Carducci MA; Philips GK
    Clin Interv Aging; 2012; 7():363-72. PubMed ID: 23049248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
    Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
    Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is denosumab better than alendronate in the treatment of osteoporosis?
    Lewiecki EM
    Nat Clin Pract Rheumatol; 2009 Feb; 5(2):72-3. PubMed ID: 19092832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing the Efficacy and Safety of Denosumab with Bisphosphonates in Increasing Bone Mineral Density in Patients with Prostate Cancer and Breast Cancer on Antihormonal Treatment.
    Razaq A; Khan S; Hassan J; Malik BH; Razaq M
    Cureus; 2019 Dec; 11(12):e6401. PubMed ID: 31970031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding and optimizing bone health in breast cancer.
    Guise TA; Brufsky A; Coleman RE
    Curr Med Res Opin; 2010 Dec; 26 Suppl 3():3-20. PubMed ID: 21050131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Denosumab for treatment of breast cancer bone metastases and beyond.
    Nangia JR; Ma JD; Nguyen CM; Mendes MA; Trivedi MV
    Expert Opin Biol Ther; 2012 Apr; 12(4):491-501. PubMed ID: 22348344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Therapeutic agents for disorders of bone and calcium metabolism--Denosumab, a fully human monoclocal antibody-targeting RANKL as a therapy for cancer-induced bone diseases].
    Mera K; Ito K
    Clin Calcium; 2007 Jan; 17(1):37-46. PubMed ID: 17211092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiresorptive therapies in oncology and their effects on cancer progression.
    Bundred N
    Cancer Treat Rev; 2012 Oct; 38(6):776-86. PubMed ID: 22370427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer.
    Michaud LB
    Am J Health Syst Pharm; 2010 Apr; 67(7 Suppl 3):S20-30; quiz S31-3. PubMed ID: 20332495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of bisphosphonates in the adjuvant setting for breast cancer.
    Reeder JG; Brufsky AM
    Oncology (Williston Park); 2010 May; 24(6):462-7, 475. PubMed ID: 20568587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
    Gnant M; Pfeiler G; Dubsky PC; Hubalek M; Greil R; Jakesz R; Wette V; Balic M; Haslbauer F; Melbinger E; Bjelic-Radisic V; Artner-Matuschek S; Fitzal F; Marth C; Sevelda P; Mlineritsch B; Steger GG; Manfreda D; Exner R; Egle D; Bergh J; Kainberger F; Talbot S; Warner D; Fesl C; Singer CF;
    Lancet; 2015 Aug; 386(9992):433-43. PubMed ID: 26040499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of osteoporosis with denosumab.
    Lewiecki EM
    Maturitas; 2010 Jun; 66(2):182-6. PubMed ID: 20236778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.
    Coleman R; Finkelstein DM; Barrios C; Martin M; Iwata H; Hegg R; Glaspy J; Periañez AM; Tonkin K; Deleu I; Sohn J; Crown J; Delaloge S; Dai T; Zhou Y; Jandial D; Chan A
    Lancet Oncol; 2020 Jan; 21(1):60-72. PubMed ID: 31806543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
    Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.